Hospital
Ohiohealth Corporation
Ohiohealth Corporation was paid $72.29M by Medicaid between Jan 2018 and Dec 2024, across 340 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 19% of everything it billed.
33Billing provider infoOHIOHEALTH CORPORATION
COLUMBUS, OH 43228
COLUMBUS, OH 43228
33aNPI1972535052assigned 07/07/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$72.29M
24GClaims1,454,432
24DCodes billed340
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#14 of 101
Median peer was paid$22.32M
This provider vs. median3.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BROWNING, MICHAEL controls 15+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 185,655 | $9.28M | |
| 2019 | 189,181 | $9.43M | |
| 2020 | 131,858 | $8.27M | |
| 2021 | 148,346 | $7.99M | |
| 2022 | 154,711 | $7.94M | |
| 2023 | 392,412 | $17.92M | |
| 2024incomplete | 252,269 | $11.47M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 19% | 43,381 | 31,443 | $13.59M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 84,009 | 77,497 | $12.51M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 66,281 | 59,455 | $12.19M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.8% | 34,176 | 30,238 | $7.11M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 23,506 | 21,832 | $2.75M |
| G0378 | Hospital observation service, per hour | 2.7% | 25,172 | 10,399 | $1.92M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 7,186 | 6,102 | $1.78M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 5,605 | 4,744 | $1.63M |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.7% | 8,081 | 5,739 | $1.22M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.5% | 1,932 | 1,807 | $1.07M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.4% | 4,994 | 4,146 | $1.04M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 7,455 | 5,447 | $975K |
328 more codes
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.3% | 4,052 | $928K |
| 80053 | Comprehensive metabolic panel | <1% | 54,682 | $669K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,301 | $624K |
| 59025 | Fetal non-stress test | <1% | 3,685 | $599K |
| 93976 | <1% | 3,433 | $551K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,482 | $453K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 914 | $405K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,226 | $367K |
| 70496 | <1% | 1,009 | $312K | |
| 52356 | <1% | 106 | $300K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,527 | $292K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 35,542 | $283K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 35,170 | $269K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 15,832 | $248K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,453 | $242K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 471 | $234K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,245 | $231K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 18,849 | $224K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 45,491 | $215K |
| 84484 | <1% | 24,294 | $198K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,613 | $156K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,187 | $150K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,313 | $144K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 227 | $139K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 615 | $137K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 470 | $136K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 49,113 | $131K |
| 93458 | <1% | 127 | $131K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 661 | $130K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 28,349 | $129K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,285 | $128K |
| 36415 | Collection of venous blood by venipuncture | <1% | 102,363 | $126K |
| 71045 | Radiologic examination, chest; single view | <1% | 19,784 | $118K |
| 70491 | <1% | 351 | $113K | |
| 76642 | <1% | 721 | $107K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,806 | $101K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 95,527 | $98K |
| 96367 | <1% | 1,425 | $97K | |
| 93970 | <1% | 593 | $96K | |
| 82805 | <1% | 3,298 | $91K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,170 | $90K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 521 | $88K |
| 93971 | <1% | 1,083 | $88K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 765 | $85K |
| 10060 | <1% | 449 | $83K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 720 | $82K |
| J3490 | Unclassified drugs | <1% | 11,179 | $79K |
| 76830 | Ultrasound, transvaginal | <1% | 1,793 | $77K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 278 | $76K |
| 71271 | <1% | 371 | $73K | |
| 29848 | <1% | 45 | $73K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,331 | $72K |
| 74174 | <1% | 719 | $69K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 357 | $67K |
| 76770 | <1% | 369 | $64K | |
| 96376 | <1% | 6,636 | $62K | |
| 12001 | <1% | 389 | $62K | |
| 93017 | <1% | 657 | $62K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 281 | $61K |
| 72100 | <1% | 1,064 | $60K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 452 | $60K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 402 | $60K |
| 76536 | <1% | 454 | $58K | |
| 70498 | <1% | 1,065 | $57K | |
| 71250 | <1% | 593 | $56K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,318 | $56K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,549 | $54K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,209 | $52K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,012 | $50K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 242 | $49K |
| 73130 | <1% | 2,055 | $49K | |
| 70486 | <1% | 539 | $48K | |
| 36591 | <1% | 1,067 | $48K | |
| 73030 | <1% | 1,685 | $47K | |
| 86900 | <1% | 2,082 | $47K | |
| S0166 | Injection, olanzapine, 2.5 mg | <1% | 351 | $47K |
| 76801 | <1% | 1,507 | $46K | |
| 96368 | <1% | 715 | $45K | |
| 73560 | <1% | 2,033 | $45K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 367 | $41K |
| 94060 | <1% | 296 | $41K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,472 | $40K |
| 81001 | <1% | 64,807 | $39K | |
| 93296 | <1% | 1,697 | $39K | |
| 74420 | <1% | 295 | $39K | |
| 73610 | <1% | 1,764 | $39K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 27,330 | $36K |
| 47562 | <1% | 17 | $35K | |
| 73630 | <1% | 1,965 | $33K | |
| 97162 | <1% | 889 | $33K | |
| 84703 | <1% | 27,984 | $32K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,559 | $31K |
| 93922 | <1% | 376 | $31K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,077 | $31K |
| 73221 | <1% | 134 | $30K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 903 | $30K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 9,479 | $29K |
| 97116 | <1% | 802 | $27K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 37 | $27K |
| 97597 | <1% | 222 | $27K | |
| 64415 | <1% | 48 | $26K | |
| 97166 | <1% | 664 | $26K | |
| 12011 | <1% | 155 | $24K | |
| 82248 | <1% | 18,361 | $24K | |
| 84702 | <1% | 14,691 | $24K | |
| 83690 | <1% | 22,241 | $23K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,786 | $22K |
| 85027 | <1% | 5,397 | $22K | |
| 74018 | <1% | 633 | $21K | |
| 86850 | <1% | 2,049 | $21K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,971 | $21K |
| 94727 | <1% | 345 | $21K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 107 | $21K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 29,460 | $20K |
| 77062 | <1% | 362 | $19K | |
| 83735 | <1% | 4,532 | $19K | |
| 73502 | <1% | 829 | $19K | |
| 82077 | <1% | 3,643 | $19K | |
| 72050 | <1% | 251 | $18K | |
| 72141 | <1% | 104 | $18K | |
| 73110 | <1% | 1,127 | $18K | |
| 83880 | <1% | 2,829 | $18K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 636 | $17K |
| 94729 | <1% | 348 | $17K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,290 | $17K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,576 | $17K |
| 88307 | <1% | 120 | $17K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,077 | $17K |
| 90715 | <1% | 1,006 | $16K | |
| 97161 | <1% | 285 | $16K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,297 | $16K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 24,992 | $15K |
| J2704 | Injection, propofol, 10 mg | <1% | 12,802 | $15K |
| J3535 | Drug administered through a metered dose inhaler | <1% | 1,280 | $15K |
| 87040 | <1% | 1,414 | $14K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 505 | $13K |
| 83605 | <1% | 3,790 | $13K | |
| 64493 | <1% | 21 | $13K | |
| 72131 | <1% | 409 | $13K | |
| 82607 | <1% | 965 | $13K | |
| 85610 | <1% | 4,210 | $13K | |
| 88304 | <1% | 516 | $12K | |
| 80320 | <1% | 762 | $11K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,098 | $11K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 144 | $11K |
| 72128 | <1% | 257 | $10K | |
| 82728 | <1% | 1,066 | $10K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,997 | $10K |
| 93308 | <1% | 30 | $10K | |
| 80069 | <1% | 1,481 | $10K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 69 | $9K |
| 80051 | <1% | 6,524 | $9K | |
| 73080 | <1% | 557 | $9K | |
| 97165 | <1% | 168 | $8K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,065 | $8K |
| 99152 | <1% | 566 | $8K | |
| 80076 | <1% | 1,292 | $8K | |
| 93880 | <1% | 69 | $8K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,223 | $8K |
| 87077 | <1% | 1,500 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,965 | $7K |
| 75574 | <1% | 35 | $7K | |
| 73590 | <1% | 457 | $7K | |
| 77066 | Tomosynthesis, mammo | <1% | 398 | $7K |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | <1% | 466 | $7K |
| J1750 | Injection, iron dextran, 50 mg | <1% | 49 | $7K |
| 80143 | <1% | 1,638 | $6K | |
| 83540 | <1% | 1,071 | $6K | |
| 80179 | <1% | 1,628 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,288 | $6K |
| 36416 | <1% | 1,697 | $6K | |
| 94660 | <1% | 54 | $6K | |
| 85379 | <1% | 1,448 | $6K | |
| 82746 | <1% | 912 | $6K | |
| 72072 | <1% | 91 | $6K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,156 | $6K |
| 87210 | <1% | 1,224 | $6K | |
| 72040 | <1% | 83 | $5K | |
| 83550 | <1% | 1,064 | $5K | |
| 97167 | <1% | 119 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,821 | $5K |
| 71101 | <1% | 251 | $5K | |
| 97129 | <1% | 142 | $5K | |
| 86140 | <1% | 877 | $5K | |
| 73562 | <1% | 73 | $5K | |
| 80061 | Lipid panel | <1% | 937 | $5K |
| 76870 | <1% | 229 | $4K | |
| 12002 | <1% | 33 | $4K | |
| 87186 | <1% | 1,291 | $4K | |
| 73100 | <1% | 35 | $4K | |
| 86901 | <1% | 2,082 | $4K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 95 | $4K |
| 97163 | <1% | 137 | $4K | |
| 81002 | <1% | 1,088 | $4K | |
| 76377 | <1% | 274 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,241 | $4K |
| 87070 | <1% | 646 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,655 | $4K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,743 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,419 | $3K |
| 76820 | <1% | 63 | $3K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 139 | $3K |
| 74183 | <1% | 12 | $3K | |
| 73700 | <1% | 19 | $3K | |
| 87205 | <1% | 784 | $3K | |
| 87081 | <1% | 780 | $3K | |
| 84100 | <1% | 1,161 | $3K | |
| 51701 | <1% | 435 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,039 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,680 | $3K |
| 85730 | <1% | 1,010 | $3K | |
| 73090 | <1% | 290 | $2K | |
| 87075 | <1% | 423 | $2K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 882 | $2K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 761 | $2K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,323 | $2K |
| C1769 | Guide wire | <1% | 734 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,066 | $2K |
| 82565 | <1% | 6,748 | $2K | |
| 82947 | <1% | 7,289 | $2K | |
| 82550 | <1% | 710 | $2K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 904 | $2K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,374 | $2K |
| 80329 | <1% | 157 | $2K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 313 | $2K |
| 77061 | <1% | 51 | $2K | |
| 84439 | <1% | 449 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,958 | $2K |
| 85652 | <1% | 849 | $2K | |
| 82010 | <1% | 790 | $2K | |
| 72110 | <1% | 24 | $2K | |
| 84520 | <1% | 6,625 | $2K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,341 | $2K |
| 85018 | <1% | 3,659 | $2K | |
| 93356 | <1% | 178 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,091 | $1K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,724 | $1K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 14 | $1K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 66 | $1K |
| 82330 | <1% | 523 | $1K | |
| 85045 | <1% | 423 | $1K | |
| 87653 | <1% | 262 | $1K | |
| 76821 | <1% | 19 | $1K | |
| 73060 | <1% | 87 | $1K | |
| 82375 | <1% | 383 | $1K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 680 | $1K |
| 81025 | <1% | 400 | $1K | |
| 85007 | <1% | 212 | $1K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 770 | $1K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 2,157 | $1K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 827 | $1K |
| 83615 | <1% | 696 | $987.98 | |
| 77080 | <1% | 12 | $984.18 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 296 | $982.36 |
| 84550 | <1% | 710 | $966.56 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 872 | $939.85 |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 297 | $930.21 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 807 | $918.06 |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 96 | $908.56 |
| 88300 | <1% | 138 | $859.86 | |
| 73564 | <1% | 14 | $820.57 | |
| 82570 | <1% | 539 | $810.14 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 30 | $800.88 |
| 88342 | <1% | 188 | $767.34 | |
| 93299 | <1% | 30 | $759.39 | |
| 29125 | <1% | 77 | $654.82 | |
| 86703 | <1% | 151 | $642.09 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 928 | $626.59 |
| 86923 | <1% | 14 | $619.47 | |
| 83050 | <1% | 382 | $619.16 | |
| 84156 | <1% | 507 | $594.66 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 775 | $559.61 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 172 | $508.10 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 693 | $487.60 |
| 92610 | <1% | 16 | $472.06 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 105 | $465.06 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 261 | $456.40 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 23 | $447.72 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 204 | $432.29 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 282 | $427.13 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 379 | $398.75 |
| 73552 | <1% | 16 | $396.10 | |
| 97130 | <1% | 23 | $387.70 | |
| 90686 | <1% | 17 | $369.91 | |
| G0008 | Administration of influenza virus vaccine | <1% | 17 | $353.01 |
| 84132 | <1% | 662 | $344.82 | |
| 86780 | <1% | 95 | $300.50 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,480 | $291.80 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 346 | $268.35 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 320 | $262.22 |
| 86308 | <1% | 15 | $245.25 | |
| 80074 | <1% | 16 | $236.78 | |
| 85384 | <1% | 175 | $211.14 | |
| 15853 | <1% | 65 | $204.48 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 108 | $200.52 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 161 | $195.46 |
| 82365 | <1% | 118 | $190.08 | |
| 82435 | <1% | 409 | $174.40 | |
| 84295 | <1% | 414 | $170.66 | |
| 80177 | <1% | 26 | $163.75 | |
| 87147 | <1% | 15 | $163.08 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 119 | $128.49 |
| 86803 | <1% | 42 | $116.80 | |
| 86592 | <1% | 48 | $109.02 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 25 | $108.44 |
| J0703 | Injection, cefepime hydrochloride (b braun), not therapeutically equivalent to maxipime, 500 mg | <1% | 48 | $104.70 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 301 | $96.08 |
| 82140 | <1% | 56 | $88.32 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 46 | $85.41 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 117 | $77.36 |
| C1773 | Retrieval device, insertable (used to retrieve fractured medical devices) | <1% | 46 | $62.10 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 121 | $35.64 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 179 | $33.48 |
| 77065 | Tomosynthesis, mammo | <1% | 70 | $32.76 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 21 | $26.64 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 44 | $19.17 |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | <1% | 46 | $16.31 |
| J7999 | Compounded drug, not otherwise classified | <1% | 133 | $15.76 |
| J0612 | Injection, calcium gluconate, not otherwise specified, 10 mg | <1% | 16 | $13.94 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 18 | $5.88 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | <1% | 39 | $1.88 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 362 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 14 | $0.00 |
| 64494 | 0% | 21 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 314 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 24 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 17 | $0.00 |
| 87420 | 0% | 42 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBROWNING, MICHAEL (CFO, OHIOHEALTH)
Parent organizationDOCTORS HOSPITAL
| Provider | Location | Paid |
|---|---|---|
| Ohiohealth Corporation | Columbus, OH | $214.99M |
| Ohiohealth Corporation | Columbus, OH | $76.95M |
| Ohiohealth Corporation | Columbus, OH | $44.08M |
| Medcentral Health System | Mansfield, OH | $36.92M |
| Marion General Hospital, INC. | Marion, OH | $36.47M |
| Sheltering Arms Hospital Foundation, INC. | Athens, OH | $26.88M |
| Ohiohealth Berger Hospital LLC | Circleville, OH | $16.38M |
| Ohiohealth Corporation | Dublin, OH | $11.81M |
| Grady Memorial Hospital | Delaware, OH | $9.51M |
| Hardin Memorial Hospital | Kenton, OH | $7.27M |
| Medcentral Health System | Mansfield, OH | $3.13M |
| Madison Family Health Corporation | London, OH | $1.03M |
| Marion General Hospital, INC. | Marion, OH | $683K |
| Medcentral Health System | Mansfield, OH | $477K |
| Sheltering Arms Hospital Foundation | Athens, OH | $435K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.